Screener
Jade Biosciences JBIO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development(1) | $36,053 | $20,023 |
| General and administrative(2) | 7,392 | 3,361 |
| Total operating expenses | 43,445 | 23,384 |
| Loss from operations | (43,445) | (23,384) |
| Other income (expense): | ||
| Interest income | 3,102 | 615 |
| Change in fair value of Convertible Notes payable(3) | — | (15,400) |
| Other expense | (9) | — |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's operating income?
- Jade Biosciences (JBIO) reported operating income of -$43.45M in Q1 2026.
- How has Jade Biosciences's operating income changed year-over-year?
- Jade Biosciences's operating income decreased by 85.8% year-over-year, from -$23.38M to -$43.45M.
- What is the long-term trend for Jade Biosciences's operating income?
- Over 4 years (2021 to 2025), Jade Biosciences's operating income has grown at a 49.0% compound annual growth rate (CAGR), from -$23.02M to -$113.54M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Jade Biosciences's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude